Allogeneic Cell Therapy Technologies Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY CELL TYPE

1. 5.1. Introduction

2. 5.2. T Cells

3. 5.3. Natural Killer (NK) Cells

4. 5.4. Hematopoietic Stem Cells (HSCs)

5. 5.5. Mesenchymal Stem Cells (MSCs)

6. 5.6. Induced Pluripotent Stem Cells (iPSCs)

6. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. Gene Editing Technologies

3. 6.3. Cell Engineering & Expansion Technologies

4. 6.4. Cell Preservation & Cryopreservation

5. 6.5. Viral Vector Engineering

6. 6.6. Non-Viral Gene Delivery Systems

7. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Autoimmune Diseases

4. 7.4. Cardiovascular Diseases

5. 7.5. Neurological Disorders

6. 7.6. Rare Genetic Disorders

7. 7.7. Infectious Diseases

8. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Allogene Therapeutics Inc.

2. 10.2. Adicet Bio, Inc.

3. 10.3. CRISPR Therapeutics AG

4. 10.4. Astellas Pharma Inc.

5. 10.5. Gamida Cell Ltd.

6. 10.6. Atara Biotherapeutics, Inc.

7. 10.7. Fate Therapeutics

8. 10.8. Cellectis

9. 10.9. Celularity Inc.

10. 10.10. Century Therapeutics

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations